Sabon Alurar COVID da kuke shaka

Alurar rigakafin COVID-19 da CanSinoBIO ta shaka yana ba da fa'idodi na musamman kuma yana wakiltar sabuwar hanyar magance cutar ta COVID-19. Kyautar allura, magani mara lalacewa yana nufin samar da kariya mai sauri, na yau da kullun da yawan jama'a tare da sauƙin gudanarwa. Alurar rigakafin da aka shaka tana horar da aikin ƙwaƙwalwar ajiyar garkuwar jiki ta hanyar yin koyi da kamuwa da cuta ta dabi'a, wanda ba wai kawai yana motsa garkuwar raha da salon salula ba, amma kuma yana haifar da rigakafin mucosal yadda ya kamata don samun sau uku, cikakkiyar kariya.

Binciken ya nuna cewa haɓaka maganin da ba a kunna ba tare da Inhalation Convidecia™ yana ƙarfafa amsawar rigakafin mucosal mai ƙarfi. An gano matakin takamaiman RBD-takamaiman rigakafin IgA-dauri a cikin maganin abubuwan kwana 14 bayan alurar riga kafi.

Bayanin Nazarin Clinical

Binciken ya kasance bazuwar, ba makafi da daidaitawa, tare da masu halartar 420 da aka ba da izini ga ƙungiyoyi uku na 140. Ƙungiya ɗaya ta karɓi ƙananan kashi ɗaya (0.1 ml) na Inhalation Convidecia™ ƙungiya ɗaya ta sami babban kashi ɗaya (0.2 ml) na maganin da aka shaka; kuma rukuni na ƙarshe sun sami maganin rigakafi mara aiki wanda aka yi ta hanyar allurar ciki. Binciken ya nuna aminci da rigakafi na Inhalation Convidecia ™ a matsayin mai haɓakawa ta amfani da kashi ɗaya na biyar ko biyu na kashi biyar na nau'in ƙwayar tsoka.

Tabbatar da Aminci da Ƙwarewar CanSinoBIO's Inhaled Vaccine

Bayanan da aka samu kan sakamakon aminci sun nuna cewa an sami raguwar lokuta na munanan abubuwan da suka faru bayan haɓakar haɓakar Inhalation Convidecia™ fiye da waɗanda aka yi tare da haɓakar ɗan adam na rigakafin da ba a kunna ba. Ba a sami wasu munanan abubuwan da suka faru ba a cikin ƙungiyoyin inhalation guda biyu kwanaki 28 bayan an yi amfani da mai ƙarfafawa, kuma babu wani rahoto game da rashin aikin huhu na asibiti.

Bayanan da aka yi kan rigakafi sun nuna cewa inhaled heterologous booster ya haifar da wani matsayi mafi girma na kawar da ƙwayoyin cuta fiye da waɗanda ke da haɓaka mai kama da rigakafin da ba a kunna ba. Babu wani bambanci mai mahimmanci a cikin martanin rigakafi tsakanin ƙungiyoyin inhalation guda biyu, waɗanda suka kasance 6.7 zuwa 10.7 sau sama da wanda aka lura a cikin rukuni na uku tare da haɓakar haɗin gwiwa tsakanin kwanaki 14 da 28 bayan harbin ƙara. Bugu da ƙari, matakin ƙaddamar da ƙwayoyin rigakafi ya karu a ranar 28 bayan haɓakar inhaled a 6054.1 (95% CI 4584.1, 7995.0) don ƙungiyar ƙananan kashi da 4221.3 (2976.9, 5985.3) IU / ml don ƙungiyar masu girma. Hakanan ya nuna cewa Inhalation Convidecia ™ ya ba da babban matakin kariya daga bambance-bambancen Delta, tare da mafi girman matakan rigakafin ƙwayoyin cuta da aka haifar fiye da na ta hanyar allurar da ba a kunna ba.

Idan aka kwatanta da mai ƙara kunnawa, ƙara haɓaka takamaiman furotin na 2019-nCoV na musamman IFN-γ da IL-2 ELISA za a iya gano shi kwanaki 7 bayan haɓakar inhalation. Matakan magana na INF-γ da IL-2 a cikin rukunin masu haɓaka inhalation sun kasance sau 6 zuwa 10 da sau 4 zuwa 5 sama da waɗanda ke cikin rukunin ƙarfafa rigakafin rigakafin da ba a kunna ba, bi da bi. Yana nuna cewa idan aka kwatanta da inacated allurar rigakafin homologous booster, inhaled heterologous booster iya muhimmanci haifar da Th1-type cell rigakafi amsa, yayin da abubuwa kamar jinsi da shekaru ba su da wani tasiri a kan salon salula amsa.

Bugu da kari, matakin rigakafin RBD na musamman na ELISA wanda inhaled heterologous booster ya jawo sama sosai fiye da na allurar rigakafin homologous mai kara kuzari kwanaki 28 bayan gudanarwa, matakin rigakafin RBD a cikin rukunin inhalation mara nauyi ya kusan sau 13 fiye da na na ƙungiyar homologus alurar riga kafi.